Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001–2005 using the Japan Adult Leukemia Study Group AML201 protocols
The Japan Adult Leukemia Study Group (JALSG) AML201 protocols are regimens for remission induction and consolidation chemotherapy of acute myeloid leukemia (AML) and have been widely accepted in Japan since 2001. Management of infectious complications during chemotherapy has a key role in the supportive care of AML patients.
By using case report forms collected in December 2001 and December 2005, we retrospectively analyzed the infectious complications in adult patients treated by using the JALSG AML201 protocols against AML (excluding promyelocytic leukemia).
Of 980 patients, 80.2% experienced febrile neutropenia (FN), 8.3% bacteremia/fungemia, and 10.3% pulmonary infection at least once during remission-induction chemotherapy. Gram-positive bacteremia accounted for 65.1% of bacteremia/fungemia in 2001–2005, compared with 38.2% in 1987–1991 and 45.9% in 1992–1995. Of 750 patients, 81.9% experienced FN, 21.9% bacteremia/fungemia, and 9.1% pulmonary infection at least once during consolidation chemotherapy. During consolidation chemotherapy, bacteremia/fungemia and pulmonary infection were significantly more frequent in the high-dose cytarabine (HDAC) arm than in the conventional multiagent arm (25.9 vs. 17.9% and 12.7 vs. 7.7%, respectively). Invasive pulmonary aspergillosis accounted for 15.8% of pulmonary infections during remission induction and 19.7% during consolidation chemotherapy.
Our data suggest that patterns of infectious complications have changed between 1987 and 2005, possibly because of chemoprophylaxis with oral fluoroquinolones and improved diagnosis of invasive pulmonary aspergillosis by serum antigen analysis.
KeywordsAcute myeloid leukemia Bacteremia Febrile neutropenia Infectious complication Japan Adult Leukemia Study Group (JALSG)
This work was supported in part by a grant from the Japan Adult Leukemia Study Group.
Hideaki Kato: research design and performance, data collection and interpretation, and manuscript writing. Hiroyuki Fujita: research organization and supervision. Nobu Akiyama: data analysis. Shun-ichi Kimura, Nobuhiro Hiramoto, Naoko Hosono, Tsutomu Takahashi, Kazuyuki Shigeno, Hitoshi Minamiguchi, Junichi Miyatake, Hiroshi Handa, Yoshinobu Kanda, Minoru Yoshida, Shuichi Miyawaki, Shigeki Ohtake, Tomoki Naoe, Hitoshi Kiyoi, Itaru Matsumura, and Japan Adult Leukemia Study Group: research performance. Yasushi Miyazaki: research supervision. For a complete list of the members of the JALSG, see the supplemental Appendix.
Compliance with ethical standards
Conflicts of interest
Hideaki Kato received grants from Japan Blood Products Organization and Shionogi. Hiroyuki Fujita received honoraria from Novartis, and payment for manuscripts from Chugai Pharmaceutical. Shun-ichi Kimura received honoraria from Pfizer, Astellas, Sumitomo Dainippon Pharma, and Nippon Kayaku. Tsutomu Takahashi received grants from Chugai Pharmaceutical, Kyowa Hakko Kirin, and Astellas, honoraria from Chugai Pharmaceutical, Kyowa Hakko Kirin, Taiho Pharmaceutical and Celgene Corporation. Junichi Miyatake received honoraria from Kyowa Hakko Kirin, Celgene Corporation, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, and Chugai Pharmaceutical. Hiroshi Handa received consulting fee from Takeda Pharmaceutical and Celgene Corporation, grants and honoraria from Celgene Corporation, Takeda Pharmaceutical, Pfizer, Astellas, Sanofi, MSD, Shionogi, Daiichi Sankyo, Kyowa Hakko Kirin, Novartis, and Shire. Shunichi Miyawaki received a consulting fee from Astellas and expert testimony from Ohtsuka Pharmaceutical and Novartis. Hitoshi Kiyoi received consulting fees from Astellas and Daiichi Sankyo, grants from Chugai Pharmaceutical, Bristol-Myers Squibb, Kyowa Hakko Kirin, Zenyaku Kogyo, FUJIFILM Corporation, Nippon Boehringer Ingelheim, Astellas and Celgene Corporation, and honoraria from Bristol-Myers Squibb and Pfizer. Other authors: none to declare.
- 1.Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56–e93. https://doi.org/10.1093/cid/cir073 CrossRefPubMedGoogle Scholar
- 4.Kobayashi T, Miyawaki S, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, Minami S, Minato K, Tsubaki K, Ohmoto E, Oh H, Jinnai I, Sakamaki H, Hiraoka A, Kanamaru A, Takahashi I, Saito K, Naoe T, Yamada O, Asou N, Kageyama S, Emi N, Matsuoka A, Tomonaga M, Ohno R (2012) Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. J Clin Oncol 14:204–213. https://doi.org/10.1200/JCO.19184.108.40.206 CrossRefGoogle Scholar
- 5.Ohno R, Kobayashi T, Tanimoto M, Hiraoka A, Imai K, Asou N, Tomonaga M, Tsubaki K, Takahashi I, Kodera Y, Yoshida M, Murakami H, Naoe T, Shimoyama M, Tsukada T, Takeo T, Teshima H, Onozawa Y, Fujimoto K, Kuriyama K, Horiuchi A, Kimura I, Minami S, Miura Y, Kageyama S, Tahara T, Masaoka T, Shirakawa S, Saito H (1993) Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG). Cancer 71:3888–3895CrossRefGoogle Scholar
- 6.Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Omoto E, Kuriyama K, Hatake K, Saito K, Kanamaru A, Oh H, Ohtake S, Asou N, Sakamaki H, Yamada O, Jinnai I, Tsubaki K, Takeyama K, Hiraoka A, Matsuda S, Takahashi M, Shimazaki C, Adachi K, Kageyama S, Ohno R (1999) No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group. Int J Hematol 70:97–104PubMedGoogle Scholar
- 7.Ohtake S, Miyawaki S, Kiyoi H, Miyazaki Y, Okumura H, Matsuda S, Nagai T, Kishimoto Y, Okada M, Takahashi M, Handa H, Takeuchi J, Kageyama S, Asou N, Yagasaki F, Maeda Y, Ohnishi K, Naoe T, Ohno R (2010) Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study. Int J Hematol 91:276–283. https://doi.org/10.1007/s12185-009-0480-5 CrossRefPubMedGoogle Scholar
- 8.Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R, Japan Adult Leukemia Study Group AML 97 Study (2005) A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia. Cancer 104:2726–2734. https://doi.org/10.1002/cncr.21493 CrossRefPubMedGoogle Scholar
- 9.Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno R (2011) Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 study. Blood 117:2358–2366. https://doi.org/10.1182/blood-2010-03-273243 CrossRefPubMedGoogle Scholar
- 10.Miyawaki S, Ohtake S, Fujisawa S et al (2011) A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 study. Blood 117:2366–2373. https://doi.org/10.1182/blood-2010-07-295279 CrossRefPubMedGoogle Scholar
- 12.Fujita H, Yoshida M, Miura K, Sano T, Kito K, Takahashi M, Shigeno K, Kanda Y, Akiyama N, Hatsumi N, Ohnishi K, Miyawaki S, Naoe T (2009) Management of infection in patients with acute leukemia during chemotherapy in Japan: questionnaire analysis by the Japan adult leukemia study group. Int J Hematol 90:191–198. https://doi.org/10.1007/s12185-009-0367-5 CrossRefPubMedGoogle Scholar
- 15.Yoshida M, Akiyama N, Fujita H, Miura K, Miyatake JI, Handa H, Kito K, Takahashi M, Shigeno K, Kanda Y, Hatsumi N, Ohtake S, Sakamaki H, Ohnishi K, Miyawaki S, Ohno R, Naoe T (2011) Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group. Int J Hematol 93:66–73. https://doi.org/10.1007/s12185-010-0746-y CrossRefPubMedGoogle Scholar
- 16.Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie TA, van de Wetering MD, Kremer LCM, Leibovici L, Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group (2012) Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 1:CD004386. https://doi.org/10.1002/14651858.CD004386.pub3 CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Ministry of Health, Labor and Welfare (2015) Japan Nosocomial Infections Surveillance [in Japanese]. https://janis.mhlw.go.jp/report/open_report/2016/3/1/ken_Open_Report_201600.pdf Accessed on 25 Dec 2017
- 23.Ministry of Health, Labor and Welfare (2005) Japan Nosocomial Infections Surveillance [in Japanese]. https://janis.mhlw.go.jp/report/season/nenpou/2005/ken_note.html Accessed on 25 Dec 2017